Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

每经AI快讯，港通医疗12月12日晚间发布公告称，公司第五届第七次董事会会议于2025年12月12日在 公司会议室以现场结合通讯的方式召开。会议审议了《关于聘任公司副总经理的议案》等文件。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 （记者 贾运可） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...

证券之星消息，港通医疗(301515)12月12日在投资者关系平台上答复投资者关心的问题。 投资者提问：您好，请问截止2025年12月10日，公司股东数是多少？ 港通医疗回复：尊敬的投资者，您好！公司截至2025年12月10日股东总户数为7355户，感谢您的关注。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 （记者 王瀚黎） 每经AI快讯，港通医疗（SZ 301515，收盘价：19.84元）12月12日晚间发布公告称，公司审议通过了 《关于聘任公司副总经理的议案》，同意聘任夏沧澜先生为公司副总经理。 2025年1至6月份，港通医疗的营业收入构成为：医用洁净装备及系统占比55.69%，医用气体装备及系 统占比37.3%，医疗设备及其他产品销售占比4.06%，运维服务占比2.81%，其他业务占比0.14%。 截至发稿，港通医疗市值为20亿元。 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-063 四川港通医疗设备集团股份有限公司 关于聘任公司副总经理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）第五届董事会第 七次会议于 2025 年 12 月 12 日召开，审议通过了《关于聘任公司副总经理的议 案》，同意聘任夏沧澜先生为公司副总经理，任期自第五届董事会第七次会议审 议通过之日起至第五届董事会任期届满之日止。根据《公司法》《公司章程》等 相关法律法规的有关规定，夏沧澜先生的提名已经公司董事会提名委员会审核通 过。 特此公告。 四川港通医疗设备集团股份有限公司董事会 2025 年 12 月 12 日 简历附件： 夏沧澜先生，中国国籍，无境外永久居留权，1981 年出生，博士研究生学 历，正高级经济师。曾任上海宏联工贸有限公司加贝分公司销售代表；中达电通 股份有限公司产品维修工程师、技术支持工程师、成都产品维修处经理；菲律宾 SCJohnson 客服代表、储备经理；成都华气厚普机电设备股份有限公司总经理助 理、人力资源总监、 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）第五届董事会第 七次会议于 2025 年 12 月 12 日在公司会议室以现场结合通讯的方式召开。本次 会议通知于 2025 年 12 月 8 日以通讯方式发出，会议应出席董事 9 人，实际出席 董事 9 人（其中：刘煜强先生、魏勇先生、陈叙先生、姚刚先生、周正女士、赵 尘女士以通讯表决方式出席会议）。会议由董事长陈永先生召集并主持。本次会 议的召集、召开符合《公司法》和《公司章程》的有关规定，会议合法有效。 一、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： 证券代码：301515 证券简称：港通医疗 公告编号：2025-062 四川港通医疗设备集团股份有限公司 第五届董事会第七次会议决议公告 本议案已经公司董事会提名委员会审议通过。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于 聘任公司副总经理的公告》（公告编号：2025-063）。 表决结果为：同意 9 票，反对 0 票，弃权 0 票。 二、备查文件 ...

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) is experiencing a decline in stock performance and financial metrics, with a notable drop in revenue and net profit [1][2] - On December 10, 港通医疗's stock fell by 2.09%, with a trading volume of 19.84 million yuan, and a net financing purchase of 397,600 yuan [1] - The company's financing balance is 29.25 million yuan, accounting for 2.00% of its market capitalization, which is below the 10th percentile level over the past year, indicating a low financing level [1] Group 2 - As of November 28, the number of shareholders for 港通医疗 decreased by 5.24% to 7,481, while the average circulating shares per person increased by 5.53% to 8,426 shares [2] - For the period from January to September 2025, 港通医疗 reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, a decline of 150.92% [2] - 港通医疗 has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

证券之星消息，12月10日，深港通医疗（983035）指数报收于4415.21点，跌0.41%，成交69.72亿元， 换手率0.9%。当日该指数成份股中，上涨的有21家，可孚医疗以4.14%的涨幅领涨，下跌的有36家，先 健科技以9.14%的跌幅领跌。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向方面，深港通医疗（983035）指数成份股当日主力资金净流出合计3.82亿元，游资资金净流入 合计5337.33万元，散户资金净流入合计3.29亿元。成份股资金流向详情见下表： 深港通医疗（983035）指数十大成份股详情如下： ...

资金流向方面，深港通医疗（983035）指数成份股当日主力资金净流出合计2.3亿元，游资资金净流入 合计3861.61万元，散户资金净流入合计1.91亿元。成份股资金流向详情见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，12月9日，深港通医疗（983035）指数报收于4432.3点，跌1.49%，成交73.77亿元，换 手率0.99%。当日该指数成份股中，上涨的有7家，麦克奥迪以1.87%的涨幅领涨，下跌的有50家，先健 科技以8.38%的跌幅领跌。 深港通医疗（983035）指数十大成份股详情如下： ...